Impact of Per Oral Pyloromyotomy (POP) on Glycemic Control in Diabetes

Launched by MATTHEW ALLEMANG · Jan 4, 2021

Keywords

ClinConnect Summary

This clinical trial is studying how a specific procedure called per-oral pyloromyotomy (POP) can improve blood sugar control in people with diabetes who also have a condition called gastroparesis. Gastroparesis affects how food moves through the stomach, making it hard for some patients to manage their diabetes effectively. The trial will involve 40 participants aged 18 and older who have been diagnosed with gastroparesis and have had high average blood sugar levels (an HbA1c greater than 7.5%) over the past three months.

Eligible participants will be those who can complete the study requirements and do not have other specific conditions that would prevent them from taking part, such as being under 18 years old, using insulin pumps, or already having continuous glucose monitors. Throughout the trial, participants can expect to undergo the POP procedure and have their blood sugar levels monitored to see if this treatment helps improve their diabetes management. This study is currently recruiting, and it offers a chance for patients struggling with these conditions to potentially benefit from a new approach to their treatment.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients 18 years of age and older
• • 2. Patients with gastroparesis with an average HbA1c\> 7.5% over the past 3 months
• • 3. Patient that have a diagnosis of gastroparesis established by documented delayed gastric emptying by either a wireless motility capsule study or a nuclear gastric emptying study, with no evidence of gastric obstruction.
• • 4. Patients are able to complete all study requirements
• Exclusion Criteria:
• • 1. Patients \<18 years of age
• • 2. Patients with gastroparesis with an average HbA1c\< 7.5% over the past 3 months
• • 3. Patients unable or refuse to complete the study requirements
• • 4. Patients who are unable or refuse to wear a CGM sensor
• • 5. Patients with insulin pumps
• • 6. Patients who already use a CGM